Medicare billing address
CMS Medicare provider billing file
2360 Maryland RdWillow Grove, PA 19090
CMS public data · NPI 1164818910
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Anjali Bal, MD
Specialty
Credential
MD
NPI
1164818910
Primary source state
PA
Data retrieval date
July 28, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Anjali Bal, MD from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
2360 Maryland RdCMS Doctors & Clinicians file
2360 Maryland RdIn the 2024 CMS provider billing file, this NPI had 560 Medicare beneficiaries and 49,880 total services. The average beneficiary age was 74, and the average HCC risk score was 1.1.
Total Medicare allowed amount
$818,284.96
Total Medicare payment amount
$641,870.75
Medicare beneficiaries
560
Total services
49,880
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
69%
CMS beneficiary-panel share
Osteoporosis
63%
CMS beneficiary-panel share
Anxiety
30%
CMS beneficiary-panel share
Mood disorders
24%
CMS beneficiary-panel share
Ischemic heart disease
21%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, tocilizumab, 1 mg | 13,080 | $5.88 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12,000 | $4.54 |
| Injection, denosumab, 1 mg | 8,340 | $25.81 |
| Injection, romosozumab-aqqg, 1 mg | 5,880 | $10.84 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 1,900 | $42.75 |
| Injection, infliximab, excludes biosimilar, 10 mg | 790 | $31.55 |
| Injection, methylprednisolone acetate, 1 mg | 670 | $0.13 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 588 | $16.65 |
| Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 538 | $131.40 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 253 | $74.08 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1164818910. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Prednisone | Prednisone | 224 | 470 | $2,324.96 |
| 2 | Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 162 | 434.5 | $5,195.95 |
| 3 | Methylprednisolone | Methylprednisolone | 153 | 252.7 | $2,087.42 |
| 4 | Methotrexate | Methotrexate Sodium | 134 | 285.9 | $3,130.13 |
| 5 | Allopurinol | Allopurinol | 67 | 178 | $777.39 |
| 6 | Alendronate Sodium | Alendronate Sodium | 43 | 115.4 | $597.10 |
| 7 | Meloxicam | Meloxicam | 42 | 78 | $80.89 |
| 8 | Duloxetine Hcl | Duloxetine Hcl | 36 | 80 | $738.24 |
| 9 | Celecoxib | Celecoxib | 35 | 65 | $3,509.57 |
| 10 | Gabapentin | Gabapentin | 35 | 81 | $412.32 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Medical school
University Of Virginia School Of Medicine
Graduation year
2021
Group/practice field
Rheumatic Disease Associates,Ltd
Telehealth reported
Not reported
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.